Quarterly data report: Q3 2019
Author: Kaloyan Andonov
Deceleration in September
Monthly analysis: September 2019
The energy sector is still growing
Sector analysis: Energy
GCV brings synergies to the Big Apple
Innovative region: New York
Analysis: Rapid response to life sciences demand
In mid-October there were six Global Corporate Venturing stories on life sciences startups raising capital.
Analysis: Median size of rounds continues to grow in 2019
Our analysis shows that venturing rounds at most stages have grown their median dollar size. Later-stage rounds have experienced a much more pronounced growth.
Analysis: Asia-Pacific corporate venturing sees steady rise
A snapshot of the corporate-backed venturing activity in Asia-Pacific show it is the second most active region in terms of corporate-backed venture deals and exit count.
Analysis: The rise of corporate-backed funding initiatives
Summary of corporate-backed funding initiatives 2011-19
What summer slowdown?
Monthly analysis: July-August 2019
Telecoms poised for the advent of 5G
Sector review: Telecoms
Analysis: Life science exits maintain healthy pulse
September started out with news on several life sciences companies about to go public as well as a large acquisition deal of another one of them. This space enjoyed a great number of exits last year and the trend appears on a path to be continued through 2019.
Analysis: Dream11 to sleep on $500m deal
Fantasy sports platform Dream11 is reportedly aiming to raise a round sized at $500m to be backed by several corporate investors. The company is part of the broader gaming and eSport space which has seen growth recently.
Analysis: Bboxx fits in $50m
Solar system provider Bboxx completed a round led by Mitsubishi. This year we have seen a revival of corporate-backed deals in the solar energy tech space, which registered a slowdown last year.
Analysis: 10x Genomics files for $100m IPO
SoftBank-backed genome medical research tech provider 10x Genomics, previously backed by SoftBank, filed to go public. This may be a notable exit in burgeoning genomics and gene technology space, which has seen much corporate backing in recent years.